ストックスクリーナーアプリを入手
14.45
6.65%
-1.03
前日終値:
$15.48
開ける：
$15.35
24時間の取引高:
328.11K
Relative Volume:
1.49
時価総額：
$481.30M
収益：
$65.42M
当期純損益:
$-32.96M
株価収益率:
-11.38
EPS:
-1.27
ネットキャッシュフロー:
$-19.87M
1週間 パフォーマンス:
-0.76%
1か月 パフォーマンス:
-14.70%
6か月 パフォーマンス:
+71.62%
1年 パフォーマンス:
+7.51%
1日の値動き範囲:
$14.09
$15.38
1週間の範囲:
$14.02
$15.60
52週間の値動き範囲:
$7.5625
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Compare NPCE vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
14.45 | 515.60M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
113.29 | 195.21B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
377.32 | 141.28B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
98.49 | 123.60B | 35.48B | 4.64B | 5.41B | 3.5856 |
|
BSX
Boston Scientific Corp
|
76.28 | 113.14B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
78.98 | 45.52B | 6.07B | 1.06B | 799.60M | 1.8527 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-28 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-21 | 開始されました | UBS | Buy |
| 2024-03-14 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | 開始されました | Leerink Partners | Outperform |
| 2023-11-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-08-24 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | 開始されました | Lake Street | Buy |
| 2022-04-06 | 開始されました | Wolfe Research | Outperform |
| 2022-01-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | 開始されました | Robert W. Baird | Outperform |
| 2021-05-17 | 開始されました | JP Morgan | Overweight |
| 2021-05-17 | 開始されました | Morgan Stanley | Overweight |
| 2021-05-17 | 開始されました | SVB Leerink | Outperform |
| 2021-05-17 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Neuropace Inc (NPCE) 最新ニュース
Brain Implants Market to Reach USD 10.8 Billion by 2030 Growing - openPR.com
What’s the analyst consensus on NeuroPace Inc.Portfolio Update Report & Capital Efficient Trading Techniques - mfd.ru
How (NPCE) Movements Inform Risk Allocation Models - Stock Traders Daily
Neuropace, Inc. (NPCE) Stock Analysis: A 34% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Is NeuroPace Inc. stock a dividend growth opportunity2025 Retail Activity & Consistent Income Trade Recommendations - mfd.ru
Essex Investment Management Co. LLC Raises Holdings in NeuroPace, Inc. $NPCE - MarketBeat
How Does NeuroPace's Personalized Technology Transform Seizure Control - Kalkine Media
NeuroPace, Inc. (NASDAQ:NPCE) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Analysts’ Top Healthcare Picks: Oncolytics Biotech (ONCY), NeuroPace (NPCE) - The Globe and Mail
Aug Intraday: Is NeuroPace Inc a stock for growth or value investorsBond Market & High Conviction Buy Zone Alerts - baoquankhu1.vn
Neuropace, Inc. (NPCE) Stock Analysis: Exploring the 25.89% Potential Upside and Analyst Optimism - DirectorsTalk Interviews
Trading Systems Reacting to (NPCE) Volatility - Stock Traders Daily
How NeuroPace (NPCE) Analysts Are Quietly Rewriting The Story Behind The Stock - Yahoo Finance
NeuroPace stock price target raised to $20 from $19 at Leerink Partners By Investing.com - Investing.com Australia
NeuroPace stock price target raised to $20 from $19 at Leerink Partners - Investing.com Nigeria
Neuropace, Inc. (NPCE) Investor Outlook: A Medical Device Innovator with 26% Potential Upside - DirectorsTalk Interviews
FY2025 EPS Estimates for NeuroPace Lifted by HC Wainwright - MarketBeat
NeuroPace stock price target raised to $19 from $18 at H.C. Wainwright - Investing.com Nigeria
NeuroPace stock price target raised to $19 from $18 at H.C. Wainwright By Investing.com - Investing.com Canada
Beyond The Numbers: 5 Analysts Discuss NeuroPace Stock - Benzinga
NeuroPace price target raised to $19 from $18 at H.C. Wainwright - TipRanks
Juniper Biomedical Appoints Frank Fischer To Board - citybiz
CORRECTING and REPLACING Juniper Biomedical Wins Neuromod Prize and Welcomes Frank Fischer to Board of Directors - The AI Journal
NeuroPace, Inc. (NASDAQ:NPCE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
NeuroPace sees Q4 revenue of about $26.6M - MSN
NeuroPace stock rises as UBS reiterates Buy rating after strong Q4 revenue - Investing.com Australia
NeuroPace stock rises as UBS reiterates Buy rating after strong Q4 revenue By Investing.com - Investing.com South Africa
US-based NeuroPace revenue expected to grow 24% in Q4 2025 - Medical Buyer
Profit Recap: Will NeuroPace Inc stock benefit from M AWeekly Profit Summary & Growth Focused Stock Pick Reports - baoquankhu1.vn
NeuroPace reports 25% revenue growth for 2025, projects steady growth By Investing.com - Investing.com Nigeria
NeuroPace Reports Preliminary Q4, 2025 Revenue; Sets 2026 Guidance - marketscreener.com
NeuroPace (NASDAQ:NPCE) Shares Gap UpShould You Buy? - MarketBeat
NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook - Investing News Network
NeuroPace, Inc. Provides Earnings Guidance for the First Quarter and Full Year of Fiscal 2026 - marketscreener.com
NeuroPace reports 25% revenue growth for 2025, projects steady growth - Investing.com
NeuroPace (NASDAQ:NPCE) and Envoy Medical (NASDAQ:COCH) Critical Comparison - Defense World
NeuroPace (NASDAQ:NPCE) Stock Price Down 4.4% – What’s Next? - Defense World
Neurological Implants Market to Reach USD 12.39 Billion by 2031 | - openPR.com
Neuropace, Inc. (NPCE) Investor Outlook: Exploring the 13.5% Potential Upside in Medical Devices - DirectorsTalk Interviews
NeuroPace (NASDAQ:NPCE) Shares Down 4.4%Should You Sell? - MarketBeat
How resilient is NeuroPace Inc. stock in market downturnsDay Trade & Safe Investment Capital Preservation Plans - ulpravda.ru
When Will NeuroPace, Inc. (NASDAQ:NPCE) Turn A Profit? - 富途资讯
NeuroPace (NASDAQ:NPCE) Has Debt But No Earnings; Should You Worry? - simplywall.st
Financial Review: Vicarious Surgical (NYSE:RBOT) vs. NeuroPace (NASDAQ:NPCE) - Defense World
How NeuroPace Inc. stock performs in rate cut cyclesJuly 2025 Breakouts & Risk Managed Investment Strategies - Улправда
Is NeuroPace Inc. stock oversold or undervaluedMarket Activity Recap & Stepwise Entry/Exit Trade Alerts - ulpravda.ru
Will NeuroPace Inc. stock benefit from green energy trendsWatch List & High Conviction Investment Ideas - ulpravda.ru
Why NeuroPace Inc. stock remains undervaluedGlobal Market Influence & Low Risk Capital Appreciation - Улправда
NeuroPace (NASDAQ:NPCE) Sees Strong Trading VolumeHere's Why - MarketBeat
Neuropace Inc (NPCE) 財務データ
収益
当期純利益
現金流量
EPS
1.13%
大文字化:
|
ボリューム (24 時間):